Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial

BACKGROUND: The anti–interleukin-6 receptor-alpha antibody tocilizumab was approved for intravenous (IV) injection in the treatment of patients with systemic juvenile idiopathic arthritis (sJIA) aged 2 to 17 years based on results of a randomized controlled phase 3 trial. Tocilizumab treatment in sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Mallalieu, Navita L., Wimalasundera, Sunethra, Hsu, Joy C., Douglass, Wendy, Wells, Chris, Penades, Inmaculada Calvo, Cuttica, Ruben, Huppertz, Hans-Iko, Joos, Rik, Kimura, Yukiko, Milojevic, Diana, Rosenkranz, Margalit, Schikler, Kenneth, Constantin, Tamas, Wouters, Carine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704523/
https://www.ncbi.nlm.nih.gov/pubmed/31438986
http://dx.doi.org/10.1186/s12969-019-0364-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704523/
https://www.ncbi.nlm.nih.gov/pubmed/31438986
http://dx.doi.org/10.1186/s12969-019-0364-z

Ejemplares similares